Mystic Pharmaceuticals has obtained US patent for intranasal cartridge devices based on VersiDoser and VRx2 unit dose packaging and delivery platforms.
The new device technology facilitates delivery of drugs and biologics into the body through the nasal route.
Mystic president and CEO Timothy Sullivan said nasal vaccines will expand the market opportunity for the technology.
"Our VersiDoser and VRx2 delivery solutions are designed to enhance the patient experience by making these products safer, easier and more convenient to use," Sullivan added.
The intranasal delivery technology can be applied in vaccines for infectious diseases including pandemic or seasonal influenza and therapeutics for pain management, seizure, emesis, depression, hormone therapy and diabetes.
